Home

Tuesday, 11 March 2025

Utility App Market Size Worth $7.8 Billion By 2028 | CAGR: 7.5%

 

Utility App Market Growth & Trends

The global utility app market size is expected to reach USD 7.8 billion by 2028 and expand at a CAGR of 7.5% from 2022 to 2028. Enterprises are adopting digital technology to improve their business operations. With increasing digitalization, the importance of apps is growing mainly for their popularity and convenience. Utility apps offer the detection of hidden threats such as spyware and malware and block the wrongly behaving apps, tracking current and past network activity. Utility apps offer wide solutions that add value, ensure effective operations, and enhance the productivity of iPhone and Android applications.

Apple iOS store segment will register the highest CAGR of 8.6% from 2022 to 2028. This can be credited to the growing demand for secured operating systems from the smart phone users in U.S. and UK considering data privacy. Faster access and lucrative user interference feature are refueling the market growth. Cloud storage, automatic shopping app updates, and an access pass to expert validated advice for utility apps are reflecting the significant market growth during the forecast period.

North America held the largest revenue share in 2021 and is expected to maintain strong growth in the coming years. The U.S. is positively contributing to the growth of the regional market. The presence of well-established device manufacturing vendors is one of the key factors supporting the market growth. The rising trend in this region to adopt technologically utility apps is propelling the market growth. The market share of the U.S. is driven by the rising demand for AI-based smart utility apps. Ease of accessibility of integration apps with social media connectivity features will contribute to refueling the market growth. U.S. is one of the promising markets to launch new technology in terms of IT infrastructure and advanced research and development activities that help innovate and develop utility apps. Additionally, the ease of availability of IT resources and related technological talents are expected to contribute to the market growth.

Given the region's potential in terms of smartphone usage and internet penetration, Asia Pacific is predicted to be the fastest-growing regional market. China and India are expected to remain dominant markets with significant development potential for all players in the mobile app ecosystem. In addition, the rising disposable income, along with government initiatives like Digital India is likely to boost the regional market growth in the next few years. Furthermore, advancements in networking technology and the availability of low-cost mobile data are the two major development drivers in the region. Furthermore, numerous firms are engaging in cooperation or alliances in order to provide users with a unified platform, lowering their development and maintenance expenses.


key Request a free sample copy or view report summary: Utility App Market Report


Utility App Market Report Highlights

  • North America held the largest revenue share in 2021. The presence of well-established utility App vendors and the rise in the use of iOS platforms are major factors driving the regional market growth.

  • Apple iOS store segment will register the highest CAGR of 8.6% from 2022 to 2028. This can be credited to the growing demand for secured operating systems from smartphone users in U.S. and U.K. considering data privacy.

Utility App Market Segmentation

Grand View Research has segmented the global utility app market based on the marketplace, and region:

Utility App Marketplace Outlook (Revenue, USD Million, 2017 - 2028)

  • Google Play Store

  • Apple iOS Store

  • Others

Utility App Regional Outlook (Revenue, USD Million, 2017 - 2028)

  • North America

    • U.S.

  • Europe

    • Germany

    • France

    • U.K.

  • Asia Pacific

    • China

    • India

  • Central & South America

    • Brazil

  • Middle East & Africa

    • South Africa          

List of Key Players in the Utility App Market

  • Acer Inc.

  • Apple Inc.

  • Microsoft Corporation

  • Mobibiz

  • Magneto IT Solutions

  • LogMeIn, Inc.

  • Glasswire Inc.

  • NeatBytes

  • Proton Technologies AG

  • MiXplorer

Italy In Vitro Diagnostics Market Size Worth $3.74 Billion By 2030

 

Italy In Vitro Diagnostics Market Growth & Trends

The Italy in vitro diagnostics market size is expected to reach USD 3.74 billion by 2030, set to decline at a CAGR of -1.90% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growth is driven by the surge in demand for IVD products, owing to the increasing prevalence of target diseases and increasing awareness about early diagnostics of diseases among people. Moreover, the development of automated IVD systems for different healthcare service providers to provide accurate, precise, efficient, and error-free diagnosis is anticipated to boost the Italy IVD market in the coming years.

The Italy IVD market is likely to be supported by the increase in the development of POC tests that allow flexible, precise, easy-to-use, and speedy testing. For instance, in April 2021, DiaSorin launched the LIAISON Quick Detect COVID TrimericS Ab test and LIAISON IQ an immunodiagnostic POC reader. This test can detect specific IgG antibodies in 10 minutes. In addition, LINX DUO, developed by Menarini Diagnostics s.r.l, is a POC multi-assay automated analyzer for HbA1c and CRP testing capable of giving results in a span of a few minutes.

In addition, the companies operating in Italy IVD market are undertaking strategic initiatives such as partnerships and others to strengthen their product portfolio in point-of-care testing. For instance, in July 2020, A. Menarini Diagnostics and Skyla Corporation announced a distribution & supply agreement for LINX DUO multi-assay analyzer and LINX EVO clinical chemistry analyzer. With this partnership, Menarini is expected to strengthen its portfolio for POC diagnostics with state-of-the-art technology.

The increase in the aging population is anticipated to boost the uptake of IVD products thereby facilitating growth. The research found that the geriatric population is more susceptible to chronic diseases and according to the Instituto Superiore di Sanita, over 85% of people over 75 years suffer from chronic diseases. Some major diseases associated with aging are cardiovascular disorders, arthritis, diabetes, autoimmune disorders, and Alzheimer’s disease among others. The increasing risk of developing chronic disease is expected to further support the growth.

Furthermore, government bodies and key market players are taking favorable initiatives to facilitate healthcare services in the country. For instance, in June 2022, Sentinel diagnostics launched SENTiFIT 800 Analyzer, a high throughput and fully automated system for fecal immunochemical tests. Moreover, in April 2021, Lumos Diagnostics and DiaSorin entered into a strategic collaboration for the launch of the point-of-care portable immunoassay platform LIAISON IQ.

Request a free sample copy or view report summary:
Italy In Vitro Diagnostics Market Report

Italy In Vitro Diagnostics Market Report Highlights

  • Reagents segment held the largest market share in 2022 owing to increasing demand for clinical tests for targeted diseases
  • Based on the technology, the molecular diagnostics segment dominated Italy in vitro diagnostics (IVD) industry due to the continuous evolution in technology and market introduction of novel products
  • The blood banks segment is anticipated to exhibit the fastest growth rate owing to the rising demand for automated instruments in blood banks and increasing blood transfusions

Italy In Vitro Diagnostics Market Segmentation

Grand View Research has segmented Italy in vitro diagnostics market based on product, technology, application, and end-use:

Italy In Vitro Diagnostics Product Outlook (Revenue, USD Million, 2018–2030)

  • Instruments
  • Reagents
  • Services

Italy In Vitro Diagnostics Technology Outlook (Revenue, USD Million, 2018–2030)

  • Immunoassay
  • By Product
  • Instruments
  • Reagents
  • Services
  • By Technology
  • Radioimmunoassay (RIA)
  • Enzyme Immunoassays (EIA)/ELISA
  • Chemiluminescence Immunoassays (CLIA)
  • Fluorescence Immunoassays (FIA)
  • Rapid Test
  • Others
  • Hematology
  • By Product
  • Instruments
  • Reagents
  • Services
  • Clinical Chemistry
  • By Product
  • Instruments
  • Reagents
  • Services
  • Molecular Diagnostics/Genetics
  • By Product
  • Instruments
  • Reagents
  • Services
  • By Technology
  • Polymerase Chain Reaction (PCR)
  • Sequencing
  • Hybridization
  • Chips & Microarrays
  • TMA
  • INAAT
  • Mass Spectrometry
  • Others
  • Coagulation
  • By Product
  • Instruments
  • Reagents
  • Services
  • Microbiology
  • By Product
  • Instruments
  • Reagents
  • Services
  • Others
  • By Product
  • Instruments
  • Reagents
  • Services

Italy In Vitro Diagnostics Application Outlook (Revenue, USD Million, 2018–2030)

  • Infectious Disease
  • Diabetes
  • Oncology/Cancer
  • Cardiology
  • Nephrology
  • Autoimmune Diseases
  • Drug Testing
  • Others

Italy In Vitro Diagnostics End-Use Outlook (Revenue, USD Million, 2018–2030)

  • Core Lab
  • SWA (Serum Work Area)
  • By Location
  • Public Hospitals
  • Large Private Hospitals
  • Private
  • By Location
  • Clinical Chemistry
  • Immunochemistry
  • Hematology
  • By Location
  • Public Hospitals
  • Large Private Hospitals
  • Private
  • Coagulation
  • By Location
  • Public Hospitals
  • Large Private Hospitals
  • Private
  • Urine Test
  • By Location
  • Public Hospitals
  • Large Private Hospitals
  • Private
  • Others
  • Molecular Lab
  • HPV
  • Herpetics
  • Hepatitis
  • HIV
  • NIPT
  • Others
  • Pathology Lab
  • Anatomic Pathology
  • Advanced Staining (Immunohistochemistry)
  • By Location
  • Public Hospitals
  • Large Private Hospitals
  • Private
  • Primary Staining (Hematoxylin Eosin and Histochemistry)
  • By Location
  • Public Hospitals
  • Large Private Hospitals
  • Private
  • Others
  • Blood Banks
  • SWA (Serum Work Area)
  • Molecular Test
  • Point of Care (PoC)
  • Clinics
  • Hospitals
  • Retail
  • Military Premises
  • Airports
  • Others
  • Others
  • NGS
  • Mass Spectrometry
  • Others

List of Key Players in the Italy In Vitro Diagnostics Market

  • F. Hoffmann-La Roche Ltd
  • Abbott
  • bioMerieux SA
  • Danaher
  • QIAGEN
  • BD
  • Sysmex Corporation
  • DiaSorin S.p.A.
  • The Menarini Group
  • SENTINEL CH. SpA
  • Quidel Corporation

Healthcare Contract Manufacturing Market To Reach $347.5 Billion By 2030

 

Healthcare Contract Manufacturing Market Growth & Trends

The global healthcare contract manufacturing market size is expected to reach USD 347.5 billion by 2030, expanding at a CAGR of 9.5% during the forecast period, according to a new report by Grand View Research, Inc. The changing regulatory landscape coupled with rising offshoring to emerging countries is anticipated to propel the healthcare contract manufacturing market growth over the forecast period. For instance, in June 2023, FUJIFILM Diosynth Biotechnologies announced to have a commercial office in Tokyo, offering contract development and manufacturing services for advanced therapies and biologics to Asian pharmaceutical and biotechnology companies.

Due to the emergence of infections, such as COVD-19 many organizations are attempting to accelerate production to meet the growing demand. Thus, these companies are appointing healthcare CMOs to speed up their production processes, as well as reduce their overall costs to meet the increasing demand for medical products. The worldwide effort to develop a vaccine and therapeutic agent against COVID-19 has created the greatest opportunity for many large as well as small CMOs as the pharmaceutical companies are manufacturing vaccine doses on large scale. Hence, the pandemic had a positive impact on this industry.

Increasing demand for advanced products is another factor driving the industry scale. Original Equipment Manufacturers (OEMs) are outsourcing the manufacturing activities of medical devices to third parties, mainly in developing countries to gain economic benefits. Furthermore, these regions are witnessing rising cases of chronic conditions such as heart disorders, thereby positively affecting the market growth. Changes in reimbursement schemes are some of the major factors anticipated to increase the adoption of cost containment measures by OEMs. For instance, to prevent reimbursement issues from impacting financing goals, device manufacturers are developing a well-planned reimbursement strategy in parallel with their regulatory and clinical strategies in the early phases of product development.

Request a free sample copy or view report summary:
Healthcare Contract Manufacturing Market Report

Healthcare Contract Manufacturing Market Report Highlights

  • The pharmaceutical segment dominated the market with a share of 65.1% in 2022 owing to a low manufacturing budget and highly sophisticated contract manufacturing service offerings
  • The medical devices segment is expected to be the fastest-growing segment with a CAGR of 9.7% owing to increasing pressure on OEMs to reduce costs and enhance the timeline for taking a product to market
  • Cardiology is the dominant category in the medical device contract manufacturing segment, with a revenue share of 20.6% in 2022, owing to the rising demand for cardiovascular devices as a result of the increasing prevalence of associated heart conditions
  • Asia Pacific is expected to witness lucrative growth of 10.6% from 2023 to 2030, owing to the presence of a large number of service providers, lower costs, and growing demand for medical devices in the region
  • Based on end use segment, the pharmaceutical and biopharmaceutical companies category held the highest revenue share of 55.6% in 2022. High segment shares are mainly due to the increasing rate of biologics approval across the globe, thereby boosting demand for its bulk production contract manufacturing services

Healthcare Contract Manufacturing Market Segmentation

Grand View Research has segmented the global healthcare contract manufacturing market based on type, end use, and region:

Healthcare Contract Manufacturing Type Outlook (Revenue, USD Billion, 2018–2030)

  • Medical Devices
  • Service
  • Accessories manufacturing
  • Assembly manufacturing
  • Component manufacturing
  • Device manufacturing
  • Therapeutic Area
  • Cardiology
  • Diagnostic imaging
  • Orthopedic
  • IVD
  • Ophthalmic
  • General & plastic surgery
  • Drug delivery
  • Dental
  • Endoscopy
  • Diabetes care
  • Others
  • Pharmaceutical
  • API/Bulk Drugs
  • Advanced drug delivery formulations
  • Packaging
  • Finished dose formulations
  • Solid
  • Liquid
  • Semi-solid formulations

Healthcare Contract Manufacturing End-use Outlook (Revenue, USD Billion, 2018–2030)

  • Medical Device Companies
  • Pharmaceutical & Biopharmaceutical Companies
  • Others

Healthcare Contract Manufacturing Regional Outlook (Revenue, USD Billion, 2018–2030)

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
  • Belgium
  • Netherlands
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
  • Philippines
  • Malaysia
  • New Zealand
  • Singapore
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Chile
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Israel

List of Key Players of Healthcare Contract Manufacturing Market

  • Nordson Corporation
  • Integer Holdings Corporation
  • Jabil Inc.
  • Viant Technology LLC
  • FLEX LTD.
  • Celestica Inc.
  • Sanmina Corporation
  • Plexus Corp.
  • Phillips-Medisize
  • West Pharmaceutical Services, Inc.
  • Synecco Ltd
  • Catalent, Inc.
  • Thermo Fisher Scientific Inc.
  • Recipharm AB
  • Boehringer Ingelheim International GmbH
  • Lonza
  • Samsung Biologics
  • WuXi AppTec
  • FUJIFILM Diosynth Biotechnologies
  • Cambrex Corporation